Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older (Reprinted from MMWR, vol 61, pg 394-395, 2012)

被引：0
|
作者：
不详
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2012年 / 308卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：663 / 664
页数：2
相关论文
共 50 条
  • [21] Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged ≥50 Years With Community-Acquired Pneumonia
    Sherwin, Robert L.
    Gray, Sharon
    Alexander, Ronika
    McGovern, Paul C.
    Graepel, Jay
    Pride, Michael W.
    Purdy, Jay
    Paradiso, Peter
    File, Thomas M., Jr.
    JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (11): : 1813 - 1820
  • [22] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Jaime E Ordóñez
    John J Orozco
    BMC Infectious Diseases, 14
  • [23] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)A Guide to Its Use in Older Adults
    Lesley J. Scott
    Mark Sanford
    Drugs & Aging, 2012, 29 : 847 - 855
  • [24] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) A Guide to Its Use in Older Adults
    Scott, Lesley J.
    Sanford, Mark
    DRUGS & AGING, 2012, 29 (10) : 847 - 855
  • [25] Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
    McLaughlin, John M.
    Swerdlow, David L.
    Khan, Farid
    Will, Oliver
    Curry, Aaron
    Snow, Vincenza
    Isturiz, Raul E.
    Jodar, Luis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 841 - 849
  • [26] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Ordonez, Jaime E.
    Orozco, John J.
    BMC INFECTIOUS DISEASES, 2014, 14
  • [27] Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions
    Martikainen, Janne A.
    Soini, Erkki J.
    Laine, Juha
    Ahman, Heidi
    Postila, Ville
    Klemets, Peter
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2014, 20 (04) : 333 - 341
  • [28] Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6-17 years
    Mitchell, Ruth
    Trueck, Johannes
    Pollard, Andrew J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (10) : 1451 - 1465
  • [29] Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years An open-label trial
    Shiramoto, Masanari
    Irie, Shin
    Juergens, Christine
    Yamaji, Masako
    Tamai, Satoshi
    Aizawa, Masakazu
    Belanger, Todd
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1850 - 1858
  • [30] Immunogenicity of 13-Valent Conjugate Pneumococcal Vaccine in Patients 50 Years and Older with End-Stage Renal Disease and on Dialysis
    Mitra, Subhashis
    Stein, Gary E.
    Bhupalam, Shyam
    Havlichek, Daniel H.
    CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (11) : 884 - 887
12345